NCT06106581View on ClinicalTrials.gov

A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 2, 2025

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

VLA1553 full dose

Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate

BIOLOGICAL

VLA1553 half dose

Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate

BIOLOGICAL

Control

Nimenrix

Trial Locations (3)

10306

"Instituto Dermatologico y Cirugia de la Piel Dr Huberto Bogaert Diaz IDCP", Santo Domingo

Unknown

Fundacion Dominicana de Perinatologia Fundacion Probebe, Santo Domingo

Inversiones en Investigacion Medica INVERIME, Tegucigalpa

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY

NCT06106581 - A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years | Biotech Hunter | Biotech Hunter